|1.||González-Gallego, J: 3 articles (08/2001 - 03/2000)|
|2.||Schneider, Ulf C: 2 articles (07/2009 - 04/2007)|
|3.||Schroeck, Helmut: 2 articles (07/2009 - 04/2007)|
|4.||Vajkoczy, Peter: 2 articles (07/2009 - 04/2007)|
|5.||Woitzik, Johannes: 2 articles (07/2009 - 04/2007)|
|6.||Farrell, Geoffrey C: 2 articles (06/2003 - 04/2003)|
|7.||Coverdale, Shirley A: 2 articles (06/2003 - 04/2003)|
|8.||Almar, M: 2 articles (08/2001 - 02/2001)|
|9.||Olcóz, J L: 2 articles (08/2001 - 02/2001)|
|10.||Jorquera, F: 2 articles (08/2001 - 02/2001)|
|1.||Body Weight (Weight, Body)
05/01/2004 - "The proposed photometric method of antipyrine determination in urine (under the conditions of loading with 0.5% NaCl solution at an amount of 0.5% of body weight) is sufficiently sensitive and provides information about the renal clearance of antipyrine, offering an important supplement to the data obtained by conventional methods."
08/01/1991 - "Antipyrine clearance normalized to body weight was significantly greater in children than in adults (0.91 versus 0.59 ml/min/kg; p = 0.012), but was not different when normalized to body surface area. "
04/01/1995 - "The results of the present study also show that the intrinsic clearance of antipyrine is proportional to the camel's body weight, as previously shown for other mammalian species."
04/01/1984 - "The intrinsic clearance of unbound drug (CLuint) for antipyrine in 15 mammalian species was characterized by an equation of the form, CLuint = theta 1 (body weight) theta 2 (brain weight) theta 3, where thetas are constants. "
06/01/1991 - "This suggests that a 25 mg BSP/kg body weight dose followed by 15 mg antipyrine/kg 0.5 hr later may be a feasible approach to study liver blood flow, as well as hepatic efficiency in rats."
|2.||Liver Diseases (Liver Disease)
01/30/1976 - "The plasma and renal clearance of phenazone and the 4-hydrozyphenazone excretion in urine was significantly decreased in the patients with liver disease. "
11/01/1995 - "In contrast, antipyrine was effective in identifying moderate and severe hepatic impairment; however, its clearance was not reduced in mild liver disease. "
06/01/1987 - "[Clinical variability of hepatic clearance of antipyrine and Tc-99m-HIDA in healthy persons and in those with liver diseases. "
06/01/1987 - "[Diurnal variability of hepatic clearance of antipyrine and Tc-99m-HIDA in healthy persons and in those with liver diseases. "
05/01/1998 - "Antipyrine clearance in chronic and neoplastic liver diseases: a study of 518 patients."
03/01/1996 - "A significant reduction in the total plasma clearance of antipyrine occurred from 60 to 100 days post-infection and a significant increase in mean residence time occurred by 80 days post-infection. "
12/01/1990 - "Enhanced clearance of antipyrine following infection of lambs with H contortus can be explained in at least 2 ways. "
03/01/2000 - "The effect of chronic Fasciola hepatica infection on the metabolism of antipyrine, a marker of microsomal oxidative metabolism, was investigated in male water buffaloes dosed daily with 60 F. "
06/01/1998 - "The plasma levels of IFNalpha and IFNgamma were significantly elevated from 4.7 U/ml to 12.6 U/ml and 0.3 U/ml to 3.4 U/ml, respectively, whereas the antipyrine clearance showed a decrease from 57.9 ml/min to 45 ml/min in the symptomatic interval of an acute viral infection. "
06/01/1997 - "Significant prolongation of antipyrine half life was observed 16 weeks after infection. "
11/01/1995 - "Statistically significant prolongation of the half-life, decrease in the elimination rate constant and the clearance of antipyrine have been found in the rats receiving anti-cancer drugs, as compared to the controls. "
11/01/1977 - "The mean plasma clearance of antipyrine was 0.0475 +/- 0.009 liter/kg/hr in the tumor group and 0.0557 +/- 0.007 liter/kg/hr in the control group (p greater than 0.05). "
01/01/1996 - "Only one case of non-smoking related cancer was noticed among controls and this subjects had rather slow antipyrine metabolism."
01/01/1996 - "Also 2 cases of non-smoking related cancer were observed in subjects with intermediate antipyrine metabolism. "
09/15/1992 - "The influence of cancer on antipyrine metabolism is under debate. "
05/01/1976 - "The plasma half-life and clearance of antipyrine was investigated in patients during the acute phase and again during the recovery phase of viral hepatitis. "
04/01/1994 - "Antipyrine half-life, clearance, and the area under the serum drug concentration vs time curve were not significantly different in hepatitis patients compared with the healthy subjects (hepatitis patients: t1/2 = 14.3 +/- 3.7 h, CL = 29.3 +/- 8.5 ml h-1 kg-1, AUC = 498 +/- 142 mg l-1 h). "
01/01/1977 - "The concentrations of antipyrine in plasma and saliva were equivalent in normal volunteers and in patients with acute viral hepatitis following oral doses of antipyrine. "
05/01/1976 - "Altered elimination of antipyrine in patients with acute viral hepatitis."
06/01/1980 - "The antipyrine clearance in controls was 30.1 +/- 2.5 ml/kg/h (S.E.M.), in patients with viral hepatitis 30.3 +/- 3.9 ml/kg/h and in liver cirrhosis 20.4 +/- 2.7 ml/kg/h. "
|1.||Indocyanine Green (Cardio-Green)
|2.||Cytochrome P-450 Enzyme System (Cytochrome P450)
|5.||Caffeine (No Doz)
|9.||Pindolol (LB 46)
|4.||Drug Therapy (Chemotherapy)